Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureChad Collyer, Gia Han Le, Maryam Hassan, Sabrina Wong, Roger S. McIntyre
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Zalsupindole is a nondissociative, nonhallucinogenic neuroplastogen with therapeutic effects comparable to ketamine and psychedelics
10.1021/acschemneuro.5c00667 · 2025
Intrathecal 5-methoxy-N, N-dimethyltryptamine in mice modulates 5-HT1 and 5-HT3 receptors
10.1016/0014-2999(93)90427-j · 1993
Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies
10.1111/acps.13249 · 2021
Unresolved referenced work
2026
Nociception is enhanced after low doses and reduced after high doses of the serotonin receptor agonist 5-methoxy-N,N-dimethyltryptamine
10.1016/0304-3940(80)90198-6 · 1980
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study
10.1038/s41386-025-02167-3 · 2025
Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression
10.1177/02698811261465005 · 2026
Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users
10.1016/j.drugalcdep.2010.03.015 · 2010
Towards an understanding of psychedelic-induced neuroplasticity
10.1038/s41386-022-01389-z · 2023
Effects of N,N-dimethyltryptamine on rat behaviors relevant to anxiety and depression
10.1021/acschemneuro.8b00134 · 2018
Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents
10.1021/acschemneuro.8b00692 · 2019
Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents
10.1021/acschemneuro.8b00692 · 2019
Neuropharmacology of N,N-dimethyltryptamine
10.1016/j.brainresbull.2016.04.016 · 2016
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics
2024
GH001 vs placebo in patients with treatment-resistant depression: a randomized clinical trial
10.1001/jamapsychiatry.2026.0096 · 2026
The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption
10.1177/0269881118769063 · 2018
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
10.1080/00952990.2018.1545024 · 2019
Persistent tinnitus after inhaled N,N-dimethyltryptamine (DMT)
10.1080/02791072.2020.1847366 · 2021
Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression
10.1007/s11011-025-01650-6 · 2025
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: evidence and mechanisms of action
10.1177/0269881120986422 · 2021
5-MeO-DMT: an atypical psychedelic with unique pharmacology, phenomenology & risk?
10.1007/s00213-023-06517-1 · 2025
Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder
10.1038/s41386-022-01344-y · 2022
Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine – Implications for dose considerations
10.1111/cts.13410 · 2022
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Subsensitivity of serotonin and substance P receptors involved in nociception after repeated administration of a serotonin receptor agonist
10.1007/bf01255814 · 1989
Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants
10.1038/s41386-024-02041-8 · 2025
Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants
10.1038/s41398-026-03987-7 · 2026
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial
10.1038/s41591-025-04154-z · 2026
Safety and tolerability of inhaled N,N-dimethyltryptamine (BMND01 candidate): A phase I clinical trial
10.1016/j.euroneuro.2023.12.006 · 2024
The antidepressant effects of vaporized N,N-dimethyltryptamine: an open-label pilot trial in treatment-resistant depression
10.1089/psymed.2024.0002 · 2025
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
10.1038/s41386-025-02091-6 · 2025
Unresolved referenced work
2026
Pharmacokinetics of N,N-dimethyltryptamine in Humans
10.1007/s13318-023-00822-y · 2023
Psychedelics and neural plasticity: therapeutic implications
10.1523/jneurosci.1121-22.2022 · 2022
The evolution of N, N-dimethyltryptamine: from metabolic pathways to brain connectivity
10.1007/s00213-025-06777-z · 2025
Therapeutic mechanisms of psychedelics and entactogens
10.1038/s41386-023-01666-5 · 2024
Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics
10.1177/02698811251361453 · 2026
SYRCLE'S risk of bias tool for animal studies
10.1186/1471-2288-14-43 · 2014
Treatment resistance in psychiatry: state of the art and new directions
10.1038/s41380-021-01200-3 · 2022
The role of serotonin 5-HT2A receptors in memory and cognition
10.3389/fphar.2015.00225 · doi-reference
Cardiac consequences associated with psychedelic use: a systematic review of lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and 5-hydroxytryptamine 2B-mediated valvular heart disease
10.1055/a-2794-6487 · doi-reference
A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): a systematic review
10.1016/j.jad.2024.01.142 · doi-reference
Minimizing and treating chronicity in the eating disorders: a clinical overview
10.1002/eat.20978 · doi-reference
Serotonergic psychedelics for depression: a comprehensive overview
10.1016/bs.irn.2025.04.009 · doi-reference
Safety, tolerability and subjective effects of vaporized N,N-dimethyltryptamine: a randomized double-blind clinical trial
10.1016/j.euroneuro.2025.06.002 · doi-reference
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
10.1038/s41398-023-02477-4 · doi-reference
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
10.1126/science.adf0435 · doi-reference
Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
10.1007/s00213-019-05414-w · doi-reference
Effects of DMT on mental health outcomes in healthy volunteers
10.1038/s41598-024-53363-y · doi-reference
Severe psychiatric disorders and general medical comorbidities: inflammation-related mechanisms and therapeutic opportunities
10.1042/cs20211106 · doi-reference
The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: a first look at therapeutic mechanisms of action
10.1111/adb.13386 · doi-reference
Dose-response study of N,N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale
10.1001/archpsyc.1994.03950020022002 · doi-reference
Dose-response study of N,N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects
10.1001/archpsyc.1994.03950020009001 · doi-reference
Human psychopharmacology of N,N-dimethyltryptamine
10.1016/0166-4328(96)00081-2 · doi-reference
Intranasal 5-MeO-DMT concomitant with SSRI for treatment-resistant depression: a proof-of-concept trial
10.1007/s40263-025-01250-z · doi-reference
Zalsupindole: a non-hallucinogenic psychoplastogen advancing psychedelic-inspired therapeutics
10.1021/acschemneuro.5c00707 · doi-reference
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants
10.1177/02698811241246857 · doi-reference
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED–FED survey
10.1186/s40337-025-01328-5 · doi-reference
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression
10.1177/02698811261420087 · doi-reference
Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study
10.1002/dta.1685 · doi-reference
The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
10.1111/jnc.15587 · doi-reference
Benefits and challenges of ultra-fast, short-acting psychedelics in the treatment of depression
10.1176/appi.ajp.20230890 · doi-reference
Less is more? Antidepressant effects of short-acting psychedelics
10.1038/s41386-025-02103-5 · doi-reference
Anxiety-related platform in zebrafish (Danio rerio) larvae: an integrated analysis of behavioural and molecular assay in drug screening research
10.1016/j.biopha.2026.119680 · doi-reference
Reactivations associated with the use of 5-MeO-DMT among Spanish-speaking individuals: prevalence, predictors, and emotional valence
10.1080/02791072.2025.2577305 · doi-reference
Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice
10.1038/s41380-024-02655-w · doi-reference
Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents
10.1111/j.1476-5381.1991.tb12392.x · doi-reference
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
10.1038/s41591-023-02565-4 · doi-reference
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
10.1038/s41591-021-01336-3 · doi-reference
Ayahuasca and its main component N,N-dimethyltryptamine (DMT) for the treatment of mental disorders: mechanisms of action, clinical studies, and tools to explore the human mind
10.3390/biomedicines14030506 · doi-reference
Uncovering psychedelics: from neural circuits to therapeutic applications
10.3390/ph18010130 · doi-reference
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation
10.1001/jama.284.13.1689 · doi-reference
Psychedelics for the treatment of psychiatric disorders: interpreting and translating available evidence and guidance for future research
10.1176/appi.ajp.20230902 · doi-reference
Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions
10.1002/wps.21120 · doi-reference
Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents
10.1080/14740338.2023.2248883 · doi-reference
Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents
10.1080/14740338.2023.2253144 · doi-reference
Persistence/recurrence of and remission from DSM-5 substance use disorders in the United States: substance-specific and substance-aggregated correlates
10.1016/j.jsat.2018.07.012 · doi-reference
Evidence for involvement of 5-hydroxytryptamine1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second behavior
10.1016/s0022-3565(25)21407-0 · doi-reference
The clinical characterization of the adult patient with depression aimed at personalization of management
10.1002/wps.20771 · doi-reference